4.6 Article

Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2019-322588

关键词

-

资金

  1. EPSRC [EP/M006204/1]
  2. Weston Foundation
  3. Wellcome Trust Intermediate Clinical Fellowship [097479/Z/11/Z]
  4. Wellcome Beit Prize [097479/Z/11/A]
  5. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre
  6. Thiemann foundation
  7. Monument Trust Discovery Award from Parkinson's UK
  8. NIHR Oxford Biomedical Research Centre
  9. NIHR Clinical Research Network
  10. Dementias and Neurodegenerative Diseases Research Network (DeNDRoN)
  11. EPSRC [EP/M006204/1] Funding Source: UKRI
  12. MRC [MC_EX_MR/N50192X/1, MR/M024962/1, MR/L023784/1] Funding Source: UKRI
  13. Wellcome Trust [097479/Z/11/A, 097479/Z/11/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

Objective Parkinson's disease is characterised neuropathologically by alpha-synuclein aggregation. Currently, there is no blood test to predict the underlying pathology or distinguish Parkinson's from atypical parkinsonian syndromes. We assessed the clinical utility of serum neuronal exosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other proteinopathies. Methods We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts consisting of individuals with rapid eye movement sleep behavioural disorder, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome and controls. Longitudinal samples were analysed from Parkinson's and control individuals. We developed poly(carboxybetaine-methacrylate) coated beads to isolate L1 cell adhesion molecule (L1CAM)-positive extracellular vesicles with characteristics of exosomes and used mass spectrometry or multiplexed electrochemiluminescence to measure exosomal proteins. Results Mean neuron-derived exosomal alpha-synuclein was increased by twofold in prodromal and clinical Parkinson's disease when compared with multiple system atrophy, controls or other neurodegenerative diseases. With 314 subjects in the training group and 105 in the validation group, exosomal alpha-synuclein exhibited a consistent performance (AUC=0.86) in separating clinical Parkinson's disease from controls across populations. Exosomal clusterin was elevated in subjects with non-alpha-synuclein proteinopathies. Combined neuron-derived exosomal alpha-synuclein and clusterin measurement predicted Parkinson's disease from other proteinopathies with AUC=0.98 and from multiple system atrophy with AUC=0.94. Longitudinal sample analysis showed that exosomal alpha-synuclein remains stably elevated with Parkinson's disease progression. Conclusions Increased alpha-synuclein egress in serum neuronal exosomes precedes the diagnosis of Parkinson's disease, persists with disease progression and in combination with clusterin predicts and differentiates Parkinson's disease from atypical parkinsonism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据